Key result
Hemodynamic support in conjunction with immunosuppressive and antiviral therapy resulted in complete recovery in a 17-year-old female with fulminant parvovirus B19 myocarditis.
Case Report (n=1)
Highlights a rare presentation of parvovirus B19-induced fulminant viral myocarditis mimicking myocardial infarction in a young female.
May support combined hemodynamic-immunosuppressive-antiviral therapy in fulminant parvovirus B19 myocarditis; leaves open need for controlled trials.
Myocarditis is an inflammation of the myocardium. Clinical presentation ranges from non-specific systematic symptoms to fulminant collapse and sudden death. Sudden death occurs at rates of 8.6-12% and cardiomyopathy at 9%. In active myocarditis, there is inflammatory cellular infiltrate with myocardial necrosis. The disease is distinguished by clinical presentation in fulminant and non-fulminant myocarditis. We present a rare case of a parvovirus B19-induced fulminant viral myocarditis in a young female. The patient presented with acute onset heart failure mimicking a myocardial infarction, followed by non-specific symptoms that had been misdiagnosed as urinary tract infection.
No takes yet. Share an insight, caveat, or question.
Spartalis et al. (2017) conducted a case report in Parvovirus B19-induced fulminant viral myocarditis (n=1). Hemodynamic support, intravenous immunoglobulin, and immunosuppressive therapy was evaluated on Clinical recovery. Hemodynamic support in conjunction with immunosuppressive and antiviral therapy resulted in complete recovery in a 17-year-old female with fulminant parvovirus B19 myocarditis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: